Home | News | Directories | Calendar | Maps | Contact Us | Webmail
Perelman School of Medicine at the University of Pennsylvania Advanced Search

Adam D Cohen, MD

Adam D Cohen, MD

faculty photo
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-154
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: 215-615-5853
Fax: 215-615-5887
Harvard University, 1994.
University of Pennsylvania, 1999.
Permanent link
Perelman School of Medicine > Faculty > Search

Description of Clinical Expertise

Multiple Myeloma
POEMS syndrome
Monoclonal gammopathies
Waldenstrom's Macroglobulinemia

Description of Research Expertise

Cancer immunotherapy
Cellular therapy
Phase I trials

Selected Publications

Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, Kaufman JL, Lentzsch S, Vogl DT, Gomes CL, Pascucci N, Smith DD, Orlowski RZ, Durie BG: Carfilzomib, pomalidomide, and dexamethasone (CPD) for relapsed or refractory myeloma. Blood 126: 2284-90, November 2015.

Huntington SF, Weiss BM, Vogl DT, Cohen AD, Garfall AL, Mangan PA, Doshi JA, Stadtmauer EA.: Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. Lancet Haematology Page: e408-16, October 2015.

Paul TM, Liu SV, Chong EA, Luger SM, Porter DL, Schuster SJ, Tsai DE, Nasta SD, Loren A, Frey N, Perl A, Cohen AD, Weiss BM, Stadtmauer EA, Vogl DT.: Outpatient autologous stem cell transplantation for patients with myeloma. Clinical Lymphoma, Myeloma and Leukemia Page: 536-40, September 2015.

Garfall AL, Maus MV, Hwang W-T, Lacey SF, Mahnke YD, Melenhorst JJ, Zheng Z, Vogl DT, Cohen AD, Weiss BM, Dengel K, Kerr NDS, Bagg A, Levine BL, June CH: Chimeric antigen receptor T cells against CD19 for multiple myeloma. New England Journal of Medicine 373: 1040-47, September 2015.

Benson DM, Cohen AD, Jagannath S, Munshi N, Spitzer G, Hofmeister CC, Efebera YA, Andre P, Zerbib R, Caligiuri MA: A phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma. Clinical Cancer Research 21(18): 4055-61, September 2015 Notes: May 21. [Epub ahead of print]

Lendvai NL*, Cohen AD*, Cho HJ : Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma. Bone Marrow Transplantation 50: 770-80, June 2015 Notes: *co-first authors.

Waxman AJ, Mick R, Garfall AL, Cohen A, Vogl DT, Stadtmauer EA, Weiss BM. : Classifying ultra-high risk smoldering myeloma. Leukemia 29: 751-753, March 2015.

Garfall AL, Maus MV, Lacey SF, Mahnke YD, Melenhorst JJ, Zheng Z, Vogl DT, Cohen AD, Weiss BM, Dengel K, Kerr NDS, Hwang W-T, Levine B, June CH, Stadtmauer EA: Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR)-modified autologous T cells (CTL019) in advanced multiple myeloma. J Clin Oncol 33(suppl; abstr 8517) 2015 Notes: Oral.

Cohen AD, Liedtke M, Scott EC, Kaufman JL, Landau H, Vesole DH, Gasparetto C, Lentzsch S, Gomes CL, Rosenzweig M, Sanchorawala V, Smith DD, Comenzo R, Durie D.: Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis. Clinical Lymphoma, Leukemia and Myeloma: Proceedings from 15th International Myeloma Workshop 15(Supplement 3): e59, 2015.

Merlini G, Sanchorawala V, Zonder JA, Kukreti V, Schoenland SO, Jaccard A, Dispenzieri A, Cohen AD, Berg D, Yuan Z, Hui A-M, Palladini G, Comenzo RL: Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL). Blood (ASH Annual Meeting) Page: #3450, 2014 Notes: Poster

back to top
Last updated: 07/14/2016
The Trustees of the University of Pennsylvania